It is approved for use with standard hemodialysis-, hemofiltration-, ECMO- and heart lung-machines found in hospitals worldwide.
CytoSorb comprises of several important features: An advanced biocompatible and hemocompatible porous polymer sorbent bead technology with extremely high binding capacity, documented ability to reduce a broad range of cytokines and other inflammatory mediators, bilirubin and myoglobin, and has good safety data in thousands of human treatments.
In regards to cytokine removal, the goal is to reduce, but not to eliminate cytokines to levels that are no longer toxic, while still keeping the immune system intact.
CytoSorb is a whole blood adsorber. The unique design of the CytoSorb cartridge and its adsorber beads form the basis for its functionality and high biocompatibility.
The content of the CytoSorb cartridge consists of a highly porous high-tech polymer. The tiny beads can bind to a wide range of inflammatory mediators such as cytokines, chemokines, and anaphylline toxins by virtue of their structure, provided there is a corresponding gradient between whole blood and polymer.
In CytoSorb therapy, the blood is purified by adsorption in a procedure similar to hemoperfusion. With a total surface of> 45,000 square meters (> 4 large football fields), an adsorber is able to effectively and over time (up to 24 hours) lower high cytokine levels. It is mainly hydrophobic (water-insoluble) molecules that can be removed up to a size of 55kDa. These include cytokines. The removal of these substances is concentration-dependent, so that low (physiological) cytokine levels are not affected.
High mediator plasma levels are lowered to a level where the body can re-direct the out-of-control immune response to a point where there is immune modulation and imbalances are rebalanced.
In addition, other metabolic products such as free hemoglobin, bilirubin or myoglobin can be removed from the bloodstream. Particularly important substances, such as albumin, remain largely unaffected.